Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status
Copyright © 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved..
INTRODUCTION: STK11 and KEAP1 mutations (STK11 mutant [STK11MUT] and KEAP1MUT) are among the most often mutated genes in lung adenocarcinoma (LUAD). Although STK11MUT has been associated with resistance to programmed death-(ligand)1 (PD-[L]1) inhibition in KRASMUT LUAD, its impact on immunotherapy efficacy in KRAS wild-type (KRASWT) LUAD is currently unknown. Whether KEAP1MUT differentially affects outcomes to PD-(L)1 inhibition in KRASMUT and KRASWT LUAD is also unknown.
METHODS: Clinicopathologic and genomic data were collected from September 2013 to September 2020 from patients with advanced LUAD at the Dana-Farber Cancer Institute/Massachusetts General Hospital cohort and the Memorial Sloan Kettering Cancer Center/MD Anderson Cancer Center cohort. Clinical outcomes to PD-(L)1 inhibition were analyzed according to KRAS, STK11, and KEAP1 mutation status in two independent cohorts. The Cancer Genome Atlas transcriptomic data were interrogated to identify differences in tumor gene expression and tumor immune cell subsets, respectively, according to KRAS/STK11 and KRAS/KEAP1 comutation status.
RESULTS: In the combined cohort (Dana-Farber Cancer Institute/Massachusetts General Hospital + Memorial Sloan Kettering Cancer Center/MD Anderson Cancer Center) of 1261 patients (median age = 61 y [range: 22-92], 708 women [56.1%], 1065 smokers [84.4%]), KRAS mutations were detected in 536 cases (42.5%), and deleterious STK11 and KEAP1 mutations were found in 20.6% (260 of 1261) and 19.2% (231 of 1202) of assessable cases, respectively. In each independent cohort and in the combined cohort, STK11 and KEAP1 mutations were associated with significantly worse progression-free (STK11 hazard ratio [HR] = 2.04, p < 0.0001; KEAP1 HR = 2.05, p < 0.0001) and overall (STK11 HR = 2.09, p < 0.0001; KEAP1 HR = 2.24, p < 0.0001) survival to immunotherapy uniquely among KRASMUT but not KRASWT LUADs. Gene expression ontology and immune cell enrichment analyses revealed that the presence of STK11 or KEAP1 mutations results in distinct immunophenotypes in KRASMUT, but not in KRASWT, lung cancers.
CONCLUSIONS: STK11 and KEAP1 mutations confer worse outcomes to immunotherapy among patients with KRASMUT but not among KRASWT LUAD. Tumors harboring concurrent KRAS/STK11 and KRAS/KEAP1 mutations display distinct immune profiles in terms of gene expression and immune cell infiltration.
| Errataetall: |
CommentIn: J Thorac Oncol. 2022 Mar;17(3):351-352. - PMID 35216730 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 17(2022), 3 vom: 01. März, Seite 399-410 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ricciuti, Biagio [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.04.2022 Date Revised 31.03.2024 published: Print-Electronic CommentIn: J Thorac Oncol. 2022 Mar;17(3):351-352. - PMID 35216730 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jtho.2021.10.013 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332789284 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332789284 | ||
| 003 | DE-627 | ||
| 005 | 20240331233618.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jtho.2021.10.013 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1358.xml |
| 035 | |a (DE-627)NLM332789284 | ||
| 035 | |a (NLM)34740862 | ||
| 035 | |a (PII)S1556-0864(21)03284-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ricciuti, Biagio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.04.2022 | ||
| 500 | |a Date Revised 31.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: J Thorac Oncol. 2022 Mar;17(3):351-352. - PMID 35216730 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a INTRODUCTION: STK11 and KEAP1 mutations (STK11 mutant [STK11MUT] and KEAP1MUT) are among the most often mutated genes in lung adenocarcinoma (LUAD). Although STK11MUT has been associated with resistance to programmed death-(ligand)1 (PD-[L]1) inhibition in KRASMUT LUAD, its impact on immunotherapy efficacy in KRAS wild-type (KRASWT) LUAD is currently unknown. Whether KEAP1MUT differentially affects outcomes to PD-(L)1 inhibition in KRASMUT and KRASWT LUAD is also unknown | ||
| 520 | |a METHODS: Clinicopathologic and genomic data were collected from September 2013 to September 2020 from patients with advanced LUAD at the Dana-Farber Cancer Institute/Massachusetts General Hospital cohort and the Memorial Sloan Kettering Cancer Center/MD Anderson Cancer Center cohort. Clinical outcomes to PD-(L)1 inhibition were analyzed according to KRAS, STK11, and KEAP1 mutation status in two independent cohorts. The Cancer Genome Atlas transcriptomic data were interrogated to identify differences in tumor gene expression and tumor immune cell subsets, respectively, according to KRAS/STK11 and KRAS/KEAP1 comutation status | ||
| 520 | |a RESULTS: In the combined cohort (Dana-Farber Cancer Institute/Massachusetts General Hospital + Memorial Sloan Kettering Cancer Center/MD Anderson Cancer Center) of 1261 patients (median age = 61 y [range: 22-92], 708 women [56.1%], 1065 smokers [84.4%]), KRAS mutations were detected in 536 cases (42.5%), and deleterious STK11 and KEAP1 mutations were found in 20.6% (260 of 1261) and 19.2% (231 of 1202) of assessable cases, respectively. In each independent cohort and in the combined cohort, STK11 and KEAP1 mutations were associated with significantly worse progression-free (STK11 hazard ratio [HR] = 2.04, p < 0.0001; KEAP1 HR = 2.05, p < 0.0001) and overall (STK11 HR = 2.09, p < 0.0001; KEAP1 HR = 2.24, p < 0.0001) survival to immunotherapy uniquely among KRASMUT but not KRASWT LUADs. Gene expression ontology and immune cell enrichment analyses revealed that the presence of STK11 or KEAP1 mutations results in distinct immunophenotypes in KRASMUT, but not in KRASWT, lung cancers | ||
| 520 | |a CONCLUSIONS: STK11 and KEAP1 mutations confer worse outcomes to immunotherapy among patients with KRASMUT but not among KRASWT LUAD. Tumors harboring concurrent KRAS/STK11 and KRAS/KEAP1 mutations display distinct immune profiles in terms of gene expression and immune cell infiltration | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a KEAP1 | |
| 650 | 4 | |a KRAS | |
| 650 | 4 | |a NSCLC | |
| 650 | 4 | |a PD-(L)1 blockade | |
| 650 | 4 | |a STK11 | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 650 | 7 | |a KEAP1 protein, human |2 NLM | |
| 650 | 7 | |a KRAS protein, human |2 NLM | |
| 650 | 7 | |a Kelch-Like ECH-Associated Protein 1 |2 NLM | |
| 650 | 7 | |a Ligands |2 NLM | |
| 650 | 7 | |a NF-E2-Related Factor 2 |2 NLM | |
| 650 | 7 | |a STK11 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a AMP-Activated Protein Kinase Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.11.3 |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins p21(ras) |2 NLM | |
| 650 | 7 | |a EC 3.6.5.2 |2 NLM | |
| 700 | 1 | |a Arbour, Kathryn C |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Jessica J |e verfasserin |4 aut | |
| 700 | 1 | |a Vajdi, Amir |e verfasserin |4 aut | |
| 700 | 1 | |a Vokes, Natalie |e verfasserin |4 aut | |
| 700 | 1 | |a Hong, Lingzhi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Jianjun |e verfasserin |4 aut | |
| 700 | 1 | |a Tolstorukov, Michael Y |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yvonne Y |e verfasserin |4 aut | |
| 700 | 1 | |a Spurr, Liam F |e verfasserin |4 aut | |
| 700 | 1 | |a Cherniack, Andrew D |e verfasserin |4 aut | |
| 700 | 1 | |a Recondo, Gonzalo |e verfasserin |4 aut | |
| 700 | 1 | |a Lamberti, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xinan |e verfasserin |4 aut | |
| 700 | 1 | |a Venkatraman, Deepti |e verfasserin |4 aut | |
| 700 | 1 | |a Alessi, Joao V |e verfasserin |4 aut | |
| 700 | 1 | |a Vaz, Victor R |e verfasserin |4 aut | |
| 700 | 1 | |a Rizvi, Hira |e verfasserin |4 aut | |
| 700 | 1 | |a Egger, Jacklynn |e verfasserin |4 aut | |
| 700 | 1 | |a Plodkowski, Andrew J |e verfasserin |4 aut | |
| 700 | 1 | |a Khosrowjerdi, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Digumarthy, Subba |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Hyesun |e verfasserin |4 aut | |
| 700 | 1 | |a Vaz, Nuno |e verfasserin |4 aut | |
| 700 | 1 | |a Nishino, Mizuki |e verfasserin |4 aut | |
| 700 | 1 | |a Sholl, Lynette M |e verfasserin |4 aut | |
| 700 | 1 | |a Barbie, David |e verfasserin |4 aut | |
| 700 | 1 | |a Altan, Mehmet |e verfasserin |4 aut | |
| 700 | 1 | |a Heymach, John V |e verfasserin |4 aut | |
| 700 | 1 | |a Skoulidis, Ferdinandos |e verfasserin |4 aut | |
| 700 | 1 | |a Gainor, Justin F |e verfasserin |4 aut | |
| 700 | 1 | |a Hellmann, Matthew D |e verfasserin |4 aut | |
| 700 | 1 | |a Awad, Mark M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer |d 2006 |g 17(2022), 3 vom: 01. März, Seite 399-410 |w (DE-627)NLM169435504 |x 1556-1380 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2022 |g number:3 |g day:01 |g month:03 |g pages:399-410 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jtho.2021.10.013 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2022 |e 3 |b 01 |c 03 |h 399-410 | ||